- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02539927
Validation Study of the SAGIT® Instrument in Acromegaly (SAGIT)
International Multicentre Validation Study of SAGIT® Instrument in Acromegaly
Patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. No additional assessments or tests will be required.
SAGIT® is a new instrument developed by a group of acromegaly experts to help practicing endocrinologists to manage acromegalic patients and disease activity in their clinical practice and define acromegaly staging. It reports 5 elements: Signs and symptoms - S; Associated comorbidities - A; Growth hormone (GH) concentration - G; Insulin-like growth factor 1(IGF-1) concentration -I; Tumour size- T.
The instrument has been pre evaluated during a qualitative pilot study. The purpose of the validation study is to define and validate the scoring of the SAGIT® instrument.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Liège, Belgia
- CHU de Liège
-
-
-
-
-
Rio de Janeiro, Brasil, 21941-913
- Federal University of Rio de Janeiro
-
Sao Paulo, Brasil
- University Hospital
-
São Paulo, Brasil, 0503900
- University Hospital
-
-
-
-
-
Aarhus C, Danmark, 8000
- Department of Clinical Medicine - The Department of Endocrinology and Diabetes
-
Copenhagen, Danmark, 2100
- University Hospital, Dept of Endocrinology
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90048
- Cedars-Sinai Medical Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- The Emory Pituitary Center
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Endocrinology and Metabolism
-
-
-
-
-
Bron, Frankrike, 69677
- Hopital Neuro-cardiologique
-
Le Kremlin-Bicêtre, Frankrike, 94275
- Hopital de Bicetre
-
Marseille, Frankrike, 13385
- CHU de Marseille - Hôpital de la Timone
-
Toulouse, Frankrike, 31400
- CHU Larrey
-
-
-
-
-
Montichiari, Italia, 25018
- Ospedaliera Spedali Civili di Brescia
-
Naples, Italia
- Azienda Ospedaliero Universitar a Fedderico II
-
Padova, Italia
- Azienda Ospedaliera di Padova
-
Pisa, Italia
- Azienda Ospedaliero Universitaria Pisana-Endcrinologia 2
-
Rome, Italia, 00168
- Endocrinology, University Hospital, Policlinica Gemelu
-
-
-
-
-
Leiden, Nederland, 2333 2A
- LUMC Leiden,
-
Nijmegen, Nederland
- Radbound UMC
-
Rotterdam, Nederland, 3000 CA
- Erasmus MC
-
-
-
-
-
Barcelona, Spania
- University Hospital
-
Madrid, Spania, 28046
- University Hospital
-
Santiago de Compostela, Spania
- Hospital de Condia(CHUS) RVA Ramon Baltar S/N
-
Sevilla, Spania, 41013
- University Hospital Virgen del Rocio
-
-
-
-
-
Aberdeen, Storbritannia
- Aberdeen Royal Infirmary
-
Cambridge, Storbritannia
- University Hospital
-
Cardiff, Storbritannia
- Université Hospital
-
Oxford, Storbritannia
- Endocrinology and Metabolism Churchill Hospital
-
-
-
-
-
Essen, Tyskland, 45147
- University Hospital
-
Hamburg, Tyskland, 20357
- Endoc Zentrum Fûr Endokrine Tumoren
-
Oldenburg, Tyskland, 26122
- Private Clinique
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Male or female aged 18 years-old or above at study inclusion
- Treatment-naïve and non treatment-naïve patients with a diagnosis of acromegaly
- Data required to complete the SAGIT® tool are available in the patient medical records and do not require additional assessments or tests
- Data required to complete the SAGIT® tool are recorded within the 3 months preceding the inclusion visit (6 months for MRI)
Exclusion Criteria:
- Acute uncontrolled disease requiring intensive care
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Annen
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Controlled
|
Not controlled
|
Control status yet to be clarified
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Define and validate the scoring of the SAGIT® instrument
Tidsramme: baseline
|
Evaluating the ability of the instrument to discriminate subgroups of subjects with acromegaly (controlled vs not controlled).
|
baseline
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The ability of the SAGIT® instrument to predict the occurrence of significant clinical event(s) and/or treatment change(s) over time.
Tidsramme: 2 years
|
Significant clinical event is defined as death, stroke, onset of diabetes, onset of arthritis/onset of arthritis disability, myocardial infarction and/or diagnosis of other tumor; treatment change is defined as change in therapeutic doses, in therapeutic drug class, surgery or radiotherapy.
|
2 years
|
Define SAGIT® characteristics for different groups
Tidsramme: 2 years
|
Controlled vs. non controlled.
Treatment-naïve, patients vs. currently treated vs. previously treated patients
|
2 years
|
The association between the SAGIT® tool and patients' quality of life measured using Acromegaly Quality of Life (AcroQoL) scores.
Tidsramme: 2 years
|
Acromegaly Quality of Life (AcroQoL) scores will be compared between patient groups defined according to SAGIT scoring algorithm (controlled vs. not controlled).
This comparison will be performed using t-tests for each available visit of the prospective population.
|
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S. International Multicenter Validation Study of the SAGIT(R) Instrument in Acromegaly. J Clin Endocrinol Metab. 2021 Nov 19;106(12):3555-3568. doi: 10.1210/clinem/dgab536.
- Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT(R) validation study. Pituitary. 2019 Oct;22(5):476-487. doi: 10.1007/s11102-019-00977-5.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 8-79-52030-295
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .